| # | Drug | Count |
|---|---|---|
| 0 | TACROLIMUS | 18 |
| 1 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 18 |
| 2 | TACROLIMUS OINTMENT 0.1% | 18 |
| 3 | MYCOPHENOLATE MOFETIL | 14 |
| 4 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 14 |
| 5 | AZACITIDINE | 13 |
| 6 | AZACITIDINE FOR | 13 |
| 7 | BUDESONIDE | 13 |
| 8 | CYCLOPHOSPHAMIDE | 13 |
| 9 | CYCLOPHOSPHAMIDE FOR INJECTION | 13 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | MEFENAMIC ACID | 1 | 0.0005 |
| 1 | AZACITIDINE | 13 | 0.0004 |
| 2 | INSULIN ASPART INJECTION | 1 | 0.0004 |
| 3 | FLUDARABINE PHOSPHATE | 13 | 0.0003 |
| 4 | FRUQUINTINIB | 1 | 0.0003 |
| 5 | HYDROCORTISONE SODIUM SUCCINATE | 1 | 0.0003 |
| 6 | VANCOMYCIN HYDROCHLORIDE | 2 | 0.0002 |
| 7 | CARMUSTINE | 1 | 0.0002 |
| 8 | VENETOCLAX | 13 | 0.0002 |
| 9 | RUXOLITINIB | 13 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 19 |
| 1 | Alkylating Drug [EPC] | 14 |
| 2 | BCL-2 Inhibitor [EPC] | 13 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 13 |
| 4 | Janus Kinase Inhibitor [EPC] | 13 |
| 5 | Kinase Inhibitor [EPC] | 13 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 13 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 3 |
| 8 | Platinum-based Drug [EPC] | 3 |
| 9 | Angiotensin 2 Receptor Blocker [EPC] | 2 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | BCL-2 Inhibitor [EPC] | 13 | 0.0002 |
| 1 | Tetracycline-class Antibacterial [EPC] | 1 | 0.0001 |
| 2 | Lipopeptide Antibacterial [EPC] | 1 | 0.0001 |
| 3 | Janus Kinase Inhibitor [EPC] | 13 | 0.0001 |
| 4 | GLP-2 Analog [EPC] | 1 | 0.0001 |
| 5 | Penem Antibacterial [EPC] | 2 | 0.0001 |
| 6 | Alkylating Drug [EPC] | 14 | 0.0001 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 13 | 0.0000 |
| 8 | Bile Acid [EPC] | 1 | 0.0000 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 13 | 0.0000 |